Holen Sie sich die Stockscreener-App
59.33
0.45%
-0.27
Handel nachbörslich:
59.01
-0.32
-0.54%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BMY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$59.60
Offen:
$59.12
24-Stunden-Volumen:
7.84M
Relative Volume:
0.60
Marktkapitalisierung:
$121.14B
Einnahmen:
$48.19B
Nettoeinkommen (Verlust:
$7.06B
KGV:
17.15
EPS:
3.4587
Netto-Cashflow:
$12.85B
1W Leistung:
-0.67%
1M Leistung:
-1.59%
6M Leistung:
+31.44%
1J Leistung:
+7.29%
1-Tages-Spanne:
$58.77
$59.63
1-Wochen-Bereich:
$58.77
$62.23
52-Wochen-Spanne:
$42.52
$62.89
Bristol Myers Squibb Co Stock (BMY) Company Profile
Firmenname
Bristol Myers Squibb Co
Sektor
Telefon
(609) 252-4621
Adresse
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, AZN, MRK
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
59.33 | 121.69B | 48.19B | 7.06B | 12.85B | 3.4587 |
LLY
Lilly Eli Co
|
927.06 | 835.81B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
240.97 | 585.39B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
206.69 | 369.39B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
202.83 | 315.58B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
120.85 | 298.84B | 64.93B | 18.26B | 12.36B | 7.2751 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2026-02-20 | Eingeleitet | Barclays | Overweight |
| 2026-01-07 | Hochstufung | UBS | Neutral → Buy |
| 2025-12-15 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-12-12 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Perform |
| 2025-08-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2025-04-22 | Eingeleitet | Piper Sandler | Overweight |
| 2024-12-16 | Hochstufung | Jefferies | Hold → Buy |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-13 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-07-29 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-03-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2024-02-06 | Herabstufung | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-15 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-02 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-10-27 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-10 | Eingeleitet | SVB Securities | Market Perform |
| 2023-06-28 | Eingeleitet | Daiwa Securities | Outperform |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-01-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-11-18 | Eingeleitet | Credit Suisse | Neutral |
| 2022-10-10 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-09-14 | Herabstufung | Berenberg | Buy → Hold |
| 2022-06-03 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Underweight |
| 2021-12-17 | Eingeleitet | Goldman | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-01 | Herabstufung | Argus | Buy → Hold |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | Hochstufung | Truist | Hold → Buy |
| 2020-11-16 | Hochstufung | Societe Generale | Hold → Buy |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-11-06 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2020-10-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-07-28 | Eingeleitet | Raymond James | Outperform |
| 2020-04-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-01-06 | Fortgesetzt | Citigroup | Buy |
| 2019-12-13 | Hochstufung | Argus | Hold → Buy |
| 2019-11-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-08-14 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-05-20 | Herabstufung | Argus | Buy → Hold |
| 2019-05-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-05-03 | Fortgesetzt | JP Morgan | Overweight |
| 2019-01-15 | Hochstufung | Societe Generale | Sell → Buy |
| 2018-10-22 | Herabstufung | Citigroup | Buy → Neutral |
Alle ansehen
Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten
Trump Imposes 100% Drug Tariffs: 5 Pharma Stocks That Won’t Pay a Dime - Investing.com
Scotiabank Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Maintains Target Price $60 - 富途牛牛
Pleural Diseases Market Set to Boom Rapidly by 2033 |Bristol Myers Squibb, Merck & Co., Inc., GlaxoSmithKline plc - openPR.com
Nathan Pennell: "Global and Local" Model Takes Focus During BMS Japan Visit - Oncodaily
Bristol-Myers Squibb Company (BMY) stock price, news, quote and history - uk.finance.yahoo.com
Bristol-Myers Squibb Company (BRM.F) Stock Price, News, Quote & History - Yahoo! Finance Canada
Case-By-Case Guide As Justices Eye Landmark Pharma Law - Law360
Trust Co. of Toledo NA OH Sells 55,523 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb Company (BMY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Element Squared LLC Acquires Shares of 48,420 Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb Company (BMY) latest stock news and headlines - Yahoo Finance Australia
Elkins, Bristol Myers Squibb CFO, sells $1.85 million in BMY stock - Investing.com Australia
Bristol-Myers Squibb Cancer Moves And Equity Efforts Underpin Valuation Case - Yahoo Finance UK
Growth and Income Portfolio's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol-Myers Squibb Company (BMY) Options Chain - Yahoo! Finance Canada
BRISTOL-MYERS SQUIBB CO (BMYS.VI) Q2 FY2025 earnings call transcript - finance.yahoo.com
Elkins, Bristol Myers Squibb CFO, sells $1.85 million in BMY stock By Investing.com - Investing.com South Africa
Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors - MarketWatch
Bristol-Myers Squibb Co (BMY) Shares Down 3.58% on Apr 2 - GuruFocus
Bristol Myers Squibb and Gilead Sciences are putting their media accounts into review - Ad Age
Bristol Myers Squibb Cancer Pact And Equity Push Raise Valuation Questions - simplywall.st
Bristol-Myers Squibb Co Stock (BMY) Moved Down by 3.58% on Apr 2: What Signal Does It Send? - TradingKey
Bristol-Myers Squibb (BMY) Announces Positive Data from the Phase 3 SCOUT-HCM Trial of Camzyos - Insider Monkey
Ritter Alpha, LP's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Tema Etfs LLC Has $6.89 Million Holdings in Bristol Myers Squibb Company $BMY - marketbeat.com
20,914 Shares in Bristol Myers Squibb Company $BMY Acquired by J. Safra Sarasin Holding AG - MarketBeat
F&V Capital Management LLC Boosts Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Allspring Global Investments Holdings LLC Buys 67,783 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
DF Tactical Dividend Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Janux announces development candidate nomination under Bristol Myers collab - tipranks.com
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Bristol Myers Squibb Target of Unusually High Options Trading (NYSE:BMY) - MarketBeat
Piramal Pharma Completes Acquisition of Kenalog Injectable Product from Bristol-Myers Squibb - scanx.trade
Bristol Myers Squibb (BMY) Partners with Janux on New Cancer The - GuruFocus
Janux Unveils Development Candidate in Bristol Myers Squibb Partnership, Worth $35M Milestone - Contract Pharma
Janux Therapeutics receives $35M milestone from Bristol Myers Squibb - Investing.com
Janux Therapeutics receives $35M milestone from Bristol Myers Squibb By Investing.com - Investing.com India
Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment - Yahoo Finance Singapore
Bristol Myers Squibb Company $BMY Shares Sold by Meyer Handelman Co. - MarketBeat
Advanced Renal Cell Carcinoma Treatment Market to Grow by $3.1 Billion During 2026-2030: Global Industry Assessment Featuring Pfizer, Merck & Co., Bristol-Myers Squibb, AstraZeneca, Novartis and More - finance.yahoo.com
Bristol Myers Squibb Co. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Bristol Myers Squibb Discounts Sotyktu, Zeposia, Orencia SC on Government SiteNews and Statistics - IndexBox
Bristol Myers Squibb Co. stock rises Tuesday, still underperforms market - MarketWatch
Bristol Myers Squibb Stock: Dividend Reliability and Pipeline Momentum Define Investor Appeal in 202 - AD HOC NEWS
Is Bristol Myers Squibb (BMY) Price Near US$60 Supported By Cash Flow And Earnings Models - simplywall.st
Kidney Cancer Drugs Market to Grow by $2 Billion During - globenewswire.com
Kidney Cancer Drugs Market to Grow by $2 Billion During 2026-2030: Pfizer, Novartis, Exelixis, Roche, Bristol Myers Squibb Company, and Bayer Lead the Industry - finance.yahoo.com
Ovarian Cancer Drugs Market Outlook Report 2026-2030 - GlobeNewswire
Ovarian Cancer Drugs Market Outlook Report 2026-2030 Featuring Strategic Analysis of AstraZeneca, Roche, Bristol-Myers Squibb Company, Clovis Oncology, Pfizer and Other Key Players - finance.yahoo.com
Bristol Myers Squibb launches survey on myeloma care gaps By Investing.com - Investing.com India
Mn Services Vermogensbeheer B.V. Increases Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Finanzdaten der Bristol Myers Squibb Co-Aktie (BMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.73%
0.30%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):